Skip to main content
Erschienen in: Osteoporosis International 2/2016

01.02.2016 | Original Article

Elevated incidence of fractures in women with invasive breast cancer

verfasst von: B. J. Edwards, W. J. Gradishar, M. E. Smith, J. A. Pacheco, J. Holbrook, J. M. McKoy, B. Nardone, S. Tica, V. Godinez-Puig, A. W. Rademaker, I. B. Helenowski, A. D. Bunta, P. H. Stern, S. T. Rosen, D. P. West, T. A. Guise

Erschienen in: Osteoporosis International | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study evaluates the incidence of bone fractures in women with BC.We found that women with invasive breast cancer are at an increased risk for bone fractures, with fractures most commonly occurring at lower extremity and vertebral sites. The risk is further increased in women undergoing cancer therapy.

Introduction

Bone loss and fractures in breast cancer have generally been attributed to aromatase inhibitor use. This study assessed the incidence of fractures after invasive breast cancer diagnosis and evaluated bone density and FRAX risk calculation at time of fracture occurrence.

Methods

Retrospective cohort study of women with invasive breast cancer [June 2003–December 2011] who participated in an academic hospital based genetic biobank. Demographic and clinical characteristics were abstracted from the electronic medical record (EMR).

Results

A total of 422 women with invasive breast cancer were assessed; 79 (28 %) sustained fractures during the observation period; fractures occurred at multiple skeletal sites in 27 cases (116 fractures). The incidence of fractures was 40 per 1000 person-years. Women who sustained fractures were mostly white and had a family history of osteoporosis (36.9 %, p = 0.03) or history of a prior fracture (6/79, p = 0.004). Fractures occurred 4.0 years (range 0–12 years) after cancer diagnosis. Fracture cases had femoral neck bone mineral density (BMD) of 0.72 + 0.12 g/cm2, T-score of −1.2, that is, within the low bone mass range. Fractures most commonly occurred in lower extremities, vertebral, and wrist sites. Hip fractures accounted for 11 % of fractures, occurring at a median age of 61 years.

Conclusions

Fractures occur shortly after commencing cancer therapy. Rapid bone loss associated with cancer therapy may precipitate fractures. Fractures occur at relatively higher BMD in BC. Occurrence of fractures in invasive breast cancer raises the possibility of cancer-induced impairment in bone quality.
Literatur
1.
Zurück zum Zitat Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. Jama 287(17):2215–2220CrossRefPubMed Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. Jama 287(17):2215–2220CrossRefPubMed
2.
3.
Zurück zum Zitat Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19(14):3306–3311 Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19(14):3306–3311
4.
Zurück zum Zitat Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 15(4):1341–1347 Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 15(4):1341–1347
5.
Zurück zum Zitat Ding H, Field TS (2007) Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat Rev 33(6):506–513CrossRefPubMed Ding H, Field TS (2007) Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat Rev 33(6):506–513CrossRefPubMed
6.
Zurück zum Zitat Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD (2008) Tamoxifen use and osteoporotic fracture risk: a population-based analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(32):5227–5232CrossRef Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD (2008) Tamoxifen use and osteoporotic fracture risk: a population-based analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(32):5227–5232CrossRef
7.
Zurück zum Zitat Guise TA (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist 11(10):1121–1131CrossRefPubMed Guise TA (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist 11(10):1121–1131CrossRefPubMed
9.
Zurück zum Zitat McCloskey EV (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044–1051CrossRefPubMed McCloskey EV (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044–1051CrossRefPubMed
10.
Zurück zum Zitat Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9):1802–1810CrossRefPubMed Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9):1802–1810CrossRefPubMed
11.
Zurück zum Zitat Thurlimann B, Hess D, Koberle D et al (2004) Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95—a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 85(3):247–254CrossRefPubMed Thurlimann B, Hess D, Koberle D et al (2004) Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95—a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 85(3):247–254CrossRefPubMed
12.
Zurück zum Zitat Thurlimann B, Keshaviah A, Coates AS et al (2005) Breast International Group (BIG) 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRefPubMed Thurlimann B, Keshaviah A, Coates AS et al (2005) Breast International Group (BIG) 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRefPubMed
13.
Zurück zum Zitat Edwards BJ, Raisch DW, Shankaran V et al (2011) Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 17(3):560–568CrossRef Edwards BJ, Raisch DW, Shankaran V et al (2011) Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 17(3):560–568CrossRef
14.
Zurück zum Zitat Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 15(3):955–962 Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 15(3):955–962
15.
Zurück zum Zitat Brufsky A (2011) Adjuvant bisphosphonates for early-stage breast cancer. Lancet Oncol 12(7):610–611CrossRefPubMed Brufsky A (2011) Adjuvant bisphosphonates for early-stage breast cancer. Lancet Oncol 12(7):610–611CrossRefPubMed
16.
Zurück zum Zitat Brufsky A, Harker WG, Beck JT et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(7):829–836CrossRef Brufsky A, Harker WG, Beck JT et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(7):829–836CrossRef
17.
Zurück zum Zitat Coleman R (2007) Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer 7(Suppl 1):S29–S35CrossRefPubMed Coleman R (2007) Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer 7(Suppl 1):S29–S35CrossRefPubMed
18.
Zurück zum Zitat Hershman DL, McMahon DJ, Crew KD et al (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(29):4739–4745CrossRef Hershman DL, McMahon DJ, Crew KD et al (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(29):4739–4745CrossRef
19.
Zurück zum Zitat Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 14(19):6336–6342CrossRef Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 14(19):6336–6342CrossRef
20.
Zurück zum Zitat Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(30):4875–4882CrossRef Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(30):4875–4882CrossRef
21.
Zurück zum Zitat Lipton A, Steger GG, Figueroa J et al (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(28):4431–4437CrossRef Lipton A, Steger GG, Figueroa J et al (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(28):4431–4437CrossRef
22.
Zurück zum Zitat Gralow JR, Biermann JS, Farooki A et al (2009) NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw 7(3):S1–S32, quiz S33-35 PubMedCentralPubMed Gralow JR, Biermann JS, Farooki A et al (2009) NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw 7(3):S1–S32, quiz S33-35 PubMedCentralPubMed
23.
Zurück zum Zitat Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefPubMed Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefPubMed
24.
Zurück zum Zitat Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34(1):195–202CrossRefPubMed Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34(1):195–202CrossRefPubMed
25.
Zurück zum Zitat Wainwright SA, Marshall LM, Ensrud K et al (2005) Hip fracture in women without osteoporosis. J Clin Endocr Metab 90:2787–2793CrossRefPubMed Wainwright SA, Marshall LM, Ensrud K et al (2005) Hip fracture in women without osteoporosis. J Clin Endocr Metab 90:2787–2793CrossRefPubMed
26.
Zurück zum Zitat Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. Jama 276(17):1404–1408CrossRefPubMed Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. Jama 276(17):1404–1408CrossRefPubMed
27.
Zurück zum Zitat Hadji P, Gottschalk M, Ziller V, Kalder M, Jackisch C, Wagner U (2007) Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas 56(3):312–321CrossRefPubMed Hadji P, Gottschalk M, Ziller V, Kalder M, Jackisch C, Wagner U (2007) Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas 56(3):312–321CrossRefPubMed
28.
Zurück zum Zitat Zhang Y, Kiel DP, Kreger BE et al (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336(9):611–617CrossRefPubMed Zhang Y, Kiel DP, Kreger BE et al (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336(9):611–617CrossRefPubMed
29.
Zurück zum Zitat Boutroy S, Bouxsein ML, Munoz F, Delmas PD (2005) In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90(12):6508–6515CrossRefPubMed Boutroy S, Bouxsein ML, Munoz F, Delmas PD (2005) In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90(12):6508–6515CrossRefPubMed
30.
Zurück zum Zitat Burghardt AJ, Issever AS, Schwartz AV et al (2010) High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95(11):5045–5055PubMedCentralCrossRefPubMed Burghardt AJ, Issever AS, Schwartz AV et al (2010) High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95(11):5045–5055PubMedCentralCrossRefPubMed
31.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2009) Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 84(1):45–55CrossRefPubMed Vestergaard P, Rejnmark L, Mosekilde L (2009) Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 84(1):45–55CrossRefPubMed
32.
Zurück zum Zitat Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 15(7):1368–1375CrossRef Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 15(7):1368–1375CrossRef
33.
Zurück zum Zitat Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J (1991) Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 46(11):803–806PubMedCentralCrossRefPubMed Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J (1991) Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 46(11):803–806PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Guo XE, Kim CH (2002) Mechanical consequence of trabecular bone loss and its treatment: a three-dimensional model simulation. Bone 30(2):404–411CrossRefPubMed Guo XE, Kim CH (2002) Mechanical consequence of trabecular bone loss and its treatment: a three-dimensional model simulation. Bone 30(2):404–411CrossRefPubMed
35.
Zurück zum Zitat Cheung AM, Robbins J, Pruthi S, et al. Cortical porosity and estimated bone strength in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: Analyses from the nested bone strength substudy of the map.3 trial (MAP3BSS). Journal of Bone and Mineral Research. 2012;27. Cheung AM, Robbins J, Pruthi S, et al. Cortical porosity and estimated bone strength in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: Analyses from the nested bone strength substudy of the map.3 trial (MAP3BSS). Journal of Bone and Mineral Research. 2012;27.
36.
Zurück zum Zitat Hadji P, Kalder M, Kauka A, Bauer M, Ziller M, Hans D (2012) Effects of exemestane and tamoxifen treatments on bone quantity and quality in patient with breast cancer. Osteoporos Int 23:S289–S290 Hadji P, Kalder M, Kauka A, Bauer M, Ziller M, Hans D (2012) Effects of exemestane and tamoxifen treatments on bone quantity and quality in patient with breast cancer. Osteoporos Int 23:S289–S290
37.
Zurück zum Zitat Shao T, Shane ES, McMahon D et al (2012) Effects of high dose of bisphosphonate therapy on bone microarchitecture of the peripheral skeleton in women with early stage breast cancer. Cancer Res 72:6–12, 03 CrossRef Shao T, Shane ES, McMahon D et al (2012) Effects of high dose of bisphosphonate therapy on bone microarchitecture of the peripheral skeleton in women with early stage breast cancer. Cancer Res 72:6–12, 03 CrossRef
38.
Zurück zum Zitat Stein EM, Liu XS, Nickolas TL et al (2011) Abnormal microarchitecture and stiffness in postmenopausal women with ankle fractures. J Clin Endocrinol Metab 96(7):2041–2048PubMedCentralCrossRefPubMed Stein EM, Liu XS, Nickolas TL et al (2011) Abnormal microarchitecture and stiffness in postmenopausal women with ankle fractures. J Clin Endocrinol Metab 96(7):2041–2048PubMedCentralCrossRefPubMed
39.
Zurück zum Zitat Warriner AH, Patkar NM, Curtis JR et al (2011) Which fractures are most attributable to osteoporosis? J Clin Epidemiol 64(1):46–53CrossRefPubMed Warriner AH, Patkar NM, Curtis JR et al (2011) Which fractures are most attributable to osteoporosis? J Clin Epidemiol 64(1):46–53CrossRefPubMed
40.
Zurück zum Zitat Liu-Ambrose T, Eng JJ, Khan KM, Carter ND, McKay HA (2003) Older women with osteoporosis have increased postural sway and weaker quadriceps strength than counterparts with normal bone mass: overlooked determinants of fracture risk? J Gerontol A Biol Sci Med Sci 58(9):M862–M866CrossRefPubMed Liu-Ambrose T, Eng JJ, Khan KM, Carter ND, McKay HA (2003) Older women with osteoporosis have increased postural sway and weaker quadriceps strength than counterparts with normal bone mass: overlooked determinants of fracture risk? J Gerontol A Biol Sci Med Sci 58(9):M862–M866CrossRefPubMed
41.
Zurück zum Zitat Wernle JD, Damron TA, Allen MJ, Mann KA (2010) Local irradiation alters bone morphology and increases bone fragility in a mouse model. J Biomech 43(14):2738–2746CrossRefPubMed Wernle JD, Damron TA, Allen MJ, Mann KA (2010) Local irradiation alters bone morphology and increases bone fragility in a mouse model. J Biomech 43(14):2738–2746CrossRefPubMed
42.
Zurück zum Zitat Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 16(Suppl 2):S3–S7CrossRef Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 16(Suppl 2):S3–S7CrossRef
43.
Zurück zum Zitat Cummings SR, Nevitt MC (1994) Non-skeletal determinants of fractures: the potential importance of the mechanics of falls. Study of Osteoporotic Fractures Research Group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 4(1):67–70CrossRef Cummings SR, Nevitt MC (1994) Non-skeletal determinants of fractures: the potential importance of the mechanics of falls. Study of Osteoporotic Fractures Research Group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 4(1):67–70CrossRef
44.
Zurück zum Zitat Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer—a consensus paper of the Belgian Bone Club Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2007;epub. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer—a consensus paper of the Belgian Bone Club Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2007;epub.
Metadaten
Titel
Elevated incidence of fractures in women with invasive breast cancer
verfasst von
B. J. Edwards
W. J. Gradishar
M. E. Smith
J. A. Pacheco
J. Holbrook
J. M. McKoy
B. Nardone
S. Tica
V. Godinez-Puig
A. W. Rademaker
I. B. Helenowski
A. D. Bunta
P. H. Stern
S. T. Rosen
D. P. West
T. A. Guise
Publikationsdatum
01.02.2016
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 2/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3246-3

Weitere Artikel der Ausgabe 2/2016

Osteoporosis International 2/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.